BIIB FY 2023 Earnings — Biogen Inc. Revenue & Financial Results | Market Cap Arena

BIIBBiogen Inc.

$28B

FY 2023 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$9.8B-3.3% YoY

Gross Profit

$7.3B74.2% margin

Operating Income

$2.1B21.3% margin

Net Income

$1.2B11.8% margin

EPS (Diluted)

$7.97

Cash Flow

Operating Cash Flow

$1.5B

Free Cash Flow

$1.2B

Stock-Based Comp.

$264M

Balance Sheet

Total Assets

$26.8B

Total Liabilities

$12.0B

Stockholders' Equity

$14.8B

Cash & Equivalents

$1.0B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$9.8B	$10.2B	-3.3%
Gross Profit	$7.3B	$7.9B	-7.5%
Operating Income	$2.1B	$2.9B	-27.4%
Net Income	$1.2B	$3.0B	-61.9%